Welcome to our dedicated page for CORCEPT THERAPEUTICS SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Sean Maduck, President of Corcept Endocrinology, reported multiple transactions in Corcept Therapeutics (CORT) on 09/02/2025 and 09/03/2025. He exercised options to acquire 20,000 shares at $5.05 on 09/02/2025 and immediately sold portions under a 10b5-1 plan, selling 15,070 shares at a weighted average price of $70.3787 and 4,930 shares at a weighted average price of $70.8359. He purchased 228 shares under the company Purchase Plan at a closing price and received 228 restricted shares (zero price) that vest in one year. The report discloses indirect holdings via trusts and an LLC and shows tax-withheld shares upon vesting.
Joseph K. Belanoff, Chief Executive Officer and a director of Corcept Therapeutics, reported two open-market sales under a Rule 10b5-1 trading plan on 09/02/2025. The filing discloses a sale of 39,300 shares at a weighted average price of $70.5172 and a separate sale of 700 shares at a weighted average price of $71.0107. After the sales the reported beneficial ownership figures shown in the form are 2,822,070 shares and 2,821,370 shares, held indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02, over which the reporting person states he has voting power but disclaims beneficial ownership except for his pecuniary interest. The transactions were made pursuant to a 10b5-1 plan adopted November 26, 2024.
Corcept Therapeutics (CORT) reporting person Atabak Mokari, the company's Chief Financial Officer, executed purchases and experienced withholding tied to restricted stock vesting in early September 2025. On 09/02/2025 the Reporting Person purchased 200 shares under a Purchase Plan at a price established by that day's closing price ($71.38), and was also granted 200 Purchase Plan shares recorded at $0.00. On 09/03/2025 the issuer withheld 144 shares to satisfy tax-withholding obligations related to the vesting of restricted stock units. The filing states the Reporting Person beneficially owned 14,321 shares following these transactions and discloses 231, 232, and 775 shares underlying unvested restricted stock awards that vest 100% on the one-year anniversary of their grant dates if conditions are met.
Corcept Therapeutics (CORT) insider activity: Gary Charles Robb, Chief Business Officer, purchased common stock under the company's 2024 Incentive Award Plan Purchase Plan on September 2, 2025. He acquired 251 shares at a price based on the closing price of $71.38 on that date and separately acquired 251 shares under the Purchase Plan with a reported price of $0 for the restricted-plan component. On September 3, 2025 a transaction coded F shows 256 shares disposed at $71.38 for tax withholding related to vesting. Following these transactions he beneficially owned 13,610 shares directly and 11,571 shares indirectly held in a custodial account for a child. Several restricted stock awards (290, 292, 997 shares) remain unvested and vest one year after grant dates if conditions are met.
Form 144 filed for Corcept Therapeutics, Inc. (CORT) reports a proposed sale of 20,000 common shares to be executed on 09/02/2025 through Stifel Nicolaus & Company, Inc. The shares were acquired the same day by stock option exercise and paid in cash. The filing lists total outstanding shares of 105,370,000 and an aggregate market value for the proposed sale of $1,394,400.00. The notice also discloses multiple sales by the same holder, William Guyer, during the prior three months, including a sale of 35,007 shares on 08/08/2025 for $2,512,452.00. The filer certifies there is no undisclosed material adverse information.
Form 144 filed for Corcept Therapeutics, Inc. (CORT) proposes the sale of 20,000 common shares through Stifel Nicolaus & Co. on 09/02/2025. The shares were acquired the same day via stock option exercise and payment was in cash. The filing identifies the seller as Sean Maduck, who reported multiple share sales in the prior three months totaling 60,000 shares and gross proceeds of $4,321,783.00. The proposed sale lists an aggregate market value of $1,394,400.00 and indicates the issuer's shares outstanding as 105,370,000. The notice includes the seller's attestation about absence of undisclosed material adverse information.
Corcept Therapeutics (CORT) Form 144 summary: This notice reports a proposed sale of 5,000 common shares through Stifel Nicolaus & Co. with an aggregate market value of $348,600.00. The shares were acquired the same day, 09/02/2025, by stock option exercise and payment was in cash. The filing lists the issuer's total shares outstanding as 105,370,000 and indicates the intended exchange as NASDAQ. The filer previously sold several blocks of common stock in June–August 2025, totaling multiple transactions reported in the filing.
Corcept Therapeutics Inc. (CORT) filed a Form 144 notifying a proposed Rule 144 sale of 40,000 common shares through Stifel Nicolaus & Company Inc., with an aggregate market value of $2,788,800 and an approximate sale date of 09/02/2025. The filing reports the shares were acquired on 07/06/2022 by stock option exercise and paid for in cash. The filing also discloses recent sales by the same named seller, Joseph Belanoff: 40,000 shares on 06/02/2025 for $3,314,310, 615 shares on 07/17/2025 for $45,318, and 40,000 shares on 08/04/2025 for $2,742,006. The issuer’s total shares outstanding are listed as 105,370,000. The notice includes the seller’s representation that he has no undisclosed material adverse information.
Corcept Therapeutics (CORT) Chief Business Officer Gary Charles Robb reported multiple transactions on 08/22/2025. He acquired 5,000 stock options with a $3.88 exercise price that are fully exercisable and result in 5,000 underlying shares upon exercise. On the same date he sold 2,326 shares at $71.27 and had 2,674 shares withheld at ~$71.17 to satisfy exercise price and taxes from a net exercise. Following these transactions Robb directly beneficially owns 13,364 common shares and indirectly holds 11,571 shares in custodial accounts for his children. The filing notes 2,082 unvested restricted shares (grants from 2024–2025) that vest one year after each grant date if conditions are met.
Form 144 for Corcept Therapeutics (CORT) shows a proposed sale of 2,326 common shares acquired by stock option exercise on 08/22/2025, with cash payment the same day. The sale is through Fidelity Brokerage Services LLC on NASDAQ and the reported aggregate market value is $165,774.02. The filing also lists a prior sale on 06/16/2025 of 3,185 shares generating $225,402.45. The issuer’s outstanding shares are reported as 105,371,729. The filer certifies no undisclosed material adverse information is known.